摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-溴苄基甲砜 | 153435-84-8

中文名称
3-溴苄基甲砜
中文别名
——
英文名称
1-bromo-3-((methylsulfonyl)methyl)benzene
英文别名
1-bromo-3-[(methylsulfonyl)methyl]benzene;3-bromobenzyl methyl sulfone;1-bromo-3-(methylsulfonylmethyl)benzene;(3-bromophenyl)methyl methyl sulfone;3-Bromobenzylmethylsulfone
3-溴苄基甲砜化学式
CAS
153435-84-8
化学式
C8H9BrO2S
mdl
——
分子量
249.128
InChiKey
ILNDSIUAAUCZED-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    95-96°C
  • 沸点:
    409.0±28.0 °C(Predicted)
  • 密度:
    1.562±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    42.5
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    tert-butyl (4-chloro-2-ethynylphenoxy)acetate3-溴苄基甲砜哌啶 、 trans-bis(triphenylphosphine)palladium dichloride 、 盐酸 作用下, 以 1,4-二氧六环二氯甲烷 为溶剂, 反应 18.0h, 生成 {4-chloro-2-[(3-(methylsulfonylmethyl)phenyl)ethynyl]phenoxy}acetic acid
    参考文献:
    名称:
    Discovery of Potent, Selective, and Orally Bioavailable Alkynylphenoxyacetic Acid CRTH2 (DP2) Receptor Antagonists for the Treatment of Allergic Inflammatory Diseases
    摘要:
    New phenoxyacetic acid antagonists of CRTH2 are described. Following the discovery of a hit compound by a focused screening, high protein binding was identified as its main weakness. Optimization aimed at reducing serum protein binding led to the identification of several compounds that showed not only excellent affinities for the receptor (41 compounds with K-i < 10 nM) but also excellent potencies in a human whole blood assay (IC50 < 100 nM; PGD2-induced eosinophil shape change). Additional optimization of the PK characteristics led to the identification of several compounds suitable for in vivo testing. Of these, 19k and 19s were tested in two different pharmacological models (acute FITC-mediated contact hypersensitivity and ovalbumin-induced eosinophilia models) and found to be active after oral dosing (10 and 30 mg/kg).
    DOI:
    10.1021/jm200866y
  • 作为产物:
    描述:
    N'-(3-bromobenzylidene)methanesulfonohydrazide 在 iron(III) chloride 、 乙基溴化镁 作用下, 以 1,4-二氧六环 为溶剂, 以73%的产率得到3-溴苄基甲砜
    参考文献:
    名称:
    磺酰腙铁催化分解合成砜类化合物
    摘要:
    磺酰腙的Fe催化分解产生砜。该反应非常普遍,允许从各种芳基、烷基和 α,β-不饱和醛和酮制备砜。交叉实验表明,该反应是一个分子间过程,可以通过亚磺酸根阴离子对铁卡宾配合物的亲核攻击来进行。
    DOI:
    10.1002/ejoc.201001492
点击查看最新优质反应信息

文献信息

  • CYCLOALKANE-1,3-DIAMINE DERIVATIVE
    申请人:Daiichi Sankyo Company, Limited
    公开号:US20210269454A1
    公开(公告)日:2021-09-02
    The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , Ring Q 1 , W, m and n are each as defined in the description.
    本发明提供了一种具有对menin和MLL蛋白相互作用抑制作用的化合物或其药学上可接受的盐。该化合物由式(1)表示,或其药学上可接受的盐。 在式(1)中,虚线圈,R1,R2,R3,R4,R5,R6,R7,R8,环Q1,W,m和n的定义如描述中所述。
  • [EN] PHENOXY ACETIC ACID DERIVATIVES<br/>[FR] DÉRIVÉS D'ACIDE PHÉNOXYACÉTIQUE
    申请人:MERCK SERONO SA
    公开号:WO2010092043A1
    公开(公告)日:2010-08-19
    The present invention provides phenoxyacetic acid derivatives of Formula (I) for the treatment of CRTH2 related disorders and disease selected from asthma, atopic dermatitis and inflammatory dermatoses.
    本发明提供了用于治疗与CRTH2相关的疾病和疾病(包括哮喘、特应性皮炎和炎症性皮肤病)的Formula(I)的苯氧乙酸生物
  • TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE
    申请人:Hutchinson John Howard
    公开号:US20070173508A1
    公开(公告)日:2007-07-26
    Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of 5-lipoxygenase (5-LO). Also described herein are methods of using such 5-LO inhibitors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions, diseases, or disorders.
    本文描述了含有这些化合物的化合物和药物组合物,这些化合物抑制5-脂氧合酶(5-LO)的活性。本文还描述了使用这种5-LO抑制剂的方法,单独或与其他化合物结合,用于治疗呼吸系统、心血管系统和其他依赖或介导白三烯的状况、疾病或紊乱。
  • [EN] MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS<br/>[FR] COMPOSÉS DE MORPHOLINONE EN TANT QU'INHIBITEURS DE FACTEUR IXA
    申请人:MOCHIDA PHARM CO LTD
    公开号:WO2010065717A1
    公开(公告)日:2010-06-10
    The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.
    本发明提供了如下描述的化合物I的化合物,或其药用可接受的盐或溶剂。本发明还提供包含一个或多个所述化合物的药物组合物,以及使用所述化合物治疗或预防血栓、栓塞、高凝血性或纤维变化的方法。
  • HALOALKYLSULFONANILIDE DERIVATIVE
    申请人:Kai Masanori
    公开号:US20120029187A1
    公开(公告)日:2012-02-02
    Novel herbicides are provided. A haloalkylsulfonanilide derivative represented by the formula (1) or an agrochemically acceptable salt thereof: the formula (1): wherein Z is —C(R 9 )(R 10 )— or —N(R 11 )—, A is an oxygen atom, a sulfur atom or —N(R 12 )—, W is an oxygen atom or a sulfur atom, m is an integer of from 0 to 3, n is an integer of from 0 to 3, m+n is from 1 to 3, R 1 is halo C 1 -C 6 alkyl, R 2 is a hydrogen atom, C 1 -C 6 alkyl or the like, each of R 3 and R 4 is independently a hydrogen atom, C 1 -C 6 alkyl or the like, each of R 5 , R 6 , R 7 , R 8 , R 9 and R 10 is independently a hydrogen atom, a halogen, C 1 -C 6 alkyl or the like, each of R 11 and R 12 is a hydrogen atom, C 1 -C 6 alkyl, halo C 1 -C 6 alkyl or the like, and X is independently a hydrogen atom, a halogen, C 1 -C 6 alkyl, or the like.
    提供新型除草剂。 一种由式(1)表示的卤烷基磺酰苯胺生物或其农药可接受的盐: 式(1): 其中Z为—C(R9)(R10)—或—N(R11)—,A为氧原子、原子或—N(R12)—,W为氧原子或原子,m为0至3的整数,n为0至3的整数,m+n为1至3,R1为卤代C1-C6烷基,R2为氢原子、C1-C6烷基或类似物,R3和R4中的每一个独立地为氢原子、C1-C6烷基或类似物,R5、R6、R7、R8、R9和R10中的每一个独立地为氢原子、卤素、C1-C6烷基或类似物,R11和R12中的每一个为氢原子、C1-C6烷基、卤代C1-C6烷基或类似物,X独立地为氢原子、卤素、C1-C6烷基或类似物。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫